SCHEMBL4825676

SCHEMBL4825676

Cn1ncc(C=O)c1-c1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.49
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
ERN1 O75460 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
KCNN4 O15554 1/20 0.37
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
LPAR1 Q92633 1/20 0.35
PTGS1 P23219 4/20 0.35
PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4829146 0.81 NPC1 (0.48) HIF1APRMT5WDR77SMN1; SMN2KDM4E
SCHEMBL4829162 0.81 NPC1 (0.48) HIF1APRMT5WDR77SMN1; SMN2KDM4E
SCHEMBL4825652 0.79 HIF1A (0.46) HIF1AERN1SMN1; SMN2KDM4ENPC1
SCHEMBL332905 0.78 HIF1A (0.47) HIF1APRMT5WDR77ERN1SMN1; SMN2
SCHEMBL4836837 0.77 LMNA (0.46) HIF1APRMT5WDR77SMN1; SMN2KDM4E
SCHEMBL2273938 0.76 HTR2A (0.47) HIF1APRMT5WDR77HTR2AHTR2C
SCHEMBL5730469 0.75 PTGS2 (0.45) HIF1ALMNAMAPTPTGS1PTGS2
SCHEMBL3630473 0.74 NR3C2 (0.41) HIF1APRMT5WDR77ERN1KDM4E
Ethylene SCHEMBL11636345 0.74 ALDH1A1 (0.35) ERN1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL4833849 0.73 PRMT5 (0.44) HIF1APRMT5WDR77ERN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 HIF1A 1521/4885PRMT5 1308/4885WDR77 2581/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 HIF1A 1521/4885PRMT5 1308/4885WDR77 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.